Download PDF
Pharmacopsychiatry 2000; 33(4): 121-131
DOI: 10.1055/s-2000-11221
Original Paper
© Georg Thieme Verlag Stuttgart · New York

A Prospective Naturalistic Study of 326 Panic-Agoraphobic Patients Treated with Antidepressants

C. Toni1 , G. Perugi1 , F. Frare1 , B. Mata1 , B. Vitale1 , F. Mengali1 , M. Recchia2 , G. Serra2 , H. S. Akiskal3
  • 1 Department of Psychiatry, University of Pisa, Italy
  • 2 University of Milan, Italy
  • 3 International Mood Center, Department of Psychiatry at the University of California at San Diego, La Jolla, USA
Further Information

Publication History

12.10.1999

08.02.2000

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Objective: How far the results of randomized controlled studies apply to everyday care cannot be judged without regular measurements of outcomes in daily practice. We report on systematic data from a 3-year naturalistic prospective study on panic disorder-agoraphobic (PDA) patients treated with antidepressants in a setting of routine clinical practice. Our aim is to describe the evolution of PDA in relation to the treatments employed, and to explore demographic and clinical characteristics that might be predictive of outcome. Methods: 326 DSM-III-R PDA patients treated with antidepressants in a setting of routine clinical practice were included in a 3-year naturalistic prospective study. We utilized structured and semi-structures instruments, including the Structured Clinical Interview for Diagnosis and the Longitudinal Interview Follow-up Examination. The main antidepressants used were imipramine (39 %), clomipramine (28.5 %) and paroxetine (23.3 %); only 9 % of patients received other antidepressants. Results: 147 patients (45.1 %) stayed on medication throughout the entire period of the follow-up. Of those who interrupted the treatment, 38 % stayed in remission. The probability of achieving at least one remission during the 3-year follow-up period was 96.5 % for PD and 95.9 % for Agoraphobia. Relapses after a period of at least 2 months of complete remission were also common, and the probability of presenting at least one relapse during the 3-years follow-up period was 67.1 % for PD and 39 % for Agoraphobia. The longest period of remission of PD is associated with low severity, medium-lasting course in patients with an onset of the illness in young adulthood. Less severe agoraphobia associated with moderately severe panic attacks appears to confer a better control of phobic behavior. All three major drugs were reasonably well tolerated (only 9 % dropped out because of side effects), with sexual dysfunction and increased appetite being the most common side effects at the last evaluation; in the first phase of the treatment anticholinergic effects and jitteriness were more common with TCAs. Conclusion: Both classical antidepressants and paroxetine emerge as a useful treatment in the long-term management of PDA; paroxetine appears particularly useful in PDA patients because it was significantly less likely to induce jitteriness, thereby reducing barriers to compliance.

References

  • 1 Akiskal H S, Mallya G. Criteria for the “soft” bipolar spectrum: treatment implications.  Psychopharmacol Bull. 1987;  23 68-73
    PubMedGoogle Scholar
  • 2 Akiskal H S, Perugi G, Hantouche F, Haykal R H, Manning S, Connor P. The affective temperament scales of Memphis, Pisa, Paris and San Diego: progress toward a self-rated auto-questionaire version (Temps-A). J Affect Dis (in press)
    Google Scholar
  • 3 . American Psychiatric Association . Practice guideline for the treatment of patients with panic disorder.  Am J Psychiatry. 1998;  155 ((5, Suppl.)) 1-34
    PubMedGoogle Scholar
  • 4 Andreassen N C, Endicott J, Spitzer R L, Winokur G. The family history method using diagnostic criteria. Reliability and validity.  Arch Gen Psychiatry. 1977;  34 ((10)) 1229-1235
    PubMedGoogle Scholar
  • 5 Bakker A, van Balkom A J, Spinhoven P, Blaauw B M, van Dyck R. Follow up on the treatment of panic disorder with or without agoraphobia: a quantitative review.  J Nerv Ment Dis. 1998;  186 ((7)) 414-419
    CrossrefPubMedGoogle Scholar
  • 6 Ballenger J C, Davidson J R, Lecrubier Y, Nutt D J, Baldwin D S, den Boer J A, Kasper S, Shear M K. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.  J Clin Psychiatry. 1998;  59 ((Suppl. 8)) 47-54
    PubMedGoogle Scholar
  • 7 Beck A T, Sokol L, Clark D A, Berchick R, Wright F. A cross-over study of focused cognitive therapy for Panic Disorder.  Am J Psychiatry. 1992;  149 778-783
    PubMedGoogle Scholar
  • 8 Breier A, Charney D S, Heninger G R. Agoraphobia with panic attacks. Development, diagnostic stability and course of illness.  Arch Gen Psych. 1986;  43 1029-1036
    PubMedGoogle Scholar
  • 9 Breiman L, Friedman J H, Olshen R A, Stone C J. Classification and regression trees. Beltmont, California; Wadsworth 1984
  • 10 Burns E L, Thorpe G J, Cavallaro L A. Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data.  Behav Ther. 1986;  17 580-591
    PubMedGoogle Scholar
  • 11 Cassano G B, Toni C, Musetti L. Treatment of Panic Disorder. In: Biggio, G, Concas, A, Costa, E (eds) GABAergic Synaptic transmission. New York; Raven Press 1992: 449-460
    Google Scholar
  • 12 Cohen S D, Monteiro W, Marks I M. Two-year follow-up of agoraphobics after exposure and imipramine.  Br J Psychiatry. 1984;  144 276-281
    PubMedGoogle Scholar
  • 13 Coryel W, Noyes R. Placebo response in panic disorder.  Am J Psychiatry. 1988;  145 1138-1140
    PubMedGoogle Scholar
  • 14 Cowley D S, Flick S N, Roy-Byrne P P. Long-term course and outcome in panic disorder: a naturalistic follow-up study.  Anxiety. 1996;  2 13-21
    CrossrefPubMedGoogle Scholar
  • 15 Curtis G C, Massana J, Udina C, Ayuso J L, Perugi G. Maintenance of drug therapy of panic disorder.  J Psychiatric Research. 1993;  27 ((Suppl. 1)) 127-142
    PubMedGoogle Scholar
  • 16 Davidson J R. The long-term treatment of panic disorder.  J Clin Psychiatry. 1998;  59 ((Suppl. 8)) 17-21
    PubMedGoogle Scholar
  • 17 Den Boer J A, Slaap B R. Review of current treatment in panic disorder.  Int Clin Psychopharmacol. 1998;  13 ((Suppl. 4)) 25-30
    PubMedGoogle Scholar
  • 18 Dunner D, Kumar R. Paroxetine: a review of clinical experience.  Pharmacopsychiat. 1998;  31 89-101
    PubMedGoogle Scholar
  • 19 Emmelkamp P MG, Kuipers A CM. Agoraphobia: a follow-up study four years after treatment.  Br J Psychiatry. 1979;  134 352-355
    PubMedGoogle Scholar
  • 20 Faravelli C, Albanesi G. Agoraphobia with panic attacks. One year prospective follow-up.  Compr Psychiatry. 1987;  28 481-487
    CrossrefPubMedGoogle Scholar
  • 21 Faravelli C, Paterniti S, Scarpato A. 5-year prospective, naturalistic follow-up study of panic disorder.  Compr Psychiatry. 1995;  36 271-277
    CrossrefPubMedGoogle Scholar
  • 22 Fava G, Zielezny M, Savron G, Grandi S. Long-term effects of behavioral treatment for Panic Disorder with Agoraphobia.  Br J Psychiatry. 1995;  166 87-92
    PubMedGoogle Scholar
  • 23 Fyer A J, Liebowitz M R, Gorman J M. Discontinuation of alprazolam treatment in panic patients.  Am J Psychiatry. 1987;  144 303-308
    PubMedGoogle Scholar
  • 24 Goldberg C. Cognitive-behavioral therapy for panic: effectiveness and limitations.  Psychiatr Q. 1998;  69 ((1)) 23-44
    CrossrefPubMedGoogle Scholar
  • 25 Guy W. Adult personal data inventory. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville; MD, dhew 1976: 93-107
    Google Scholar
  • 26 Hafner R J. Fresh symptom emergence after intensive behaviour therapy.  Br J Psychiatry. 1976;  129 378-383
    PubMedGoogle Scholar
  • 27 Hoffart A, Hedley L M. Personality traits among panic disorder with agoraphobia patients before and after symptom-focused treatment.  J Anxiety Disord. 1997;  11 ((1)) 77-87
    CrossrefPubMedGoogle Scholar
  • 28 Katschnig H, Amering M, Stolk J M, Klerman G L, Ballenger J C, Briggs A, . et al . Long-term follow-up after a drug trial for panic disorder.  Br J Psychiatry. 1995;  167 487-494
    PubMedGoogle Scholar
  • 29 Keller M, Lavori P, Friedman B, Nielsen E, Endicott J, McDonald Scott P, . et al . The longitudinal Interval Follow-up Evaluation. A Comprehensive Method for assessing outcome in perspective longitudinal studies.  Arch Gen Psychiatry. 1987;  44 540-548
    PubMedGoogle Scholar
  • 30 Keller M B, Yonkers K A, Warshaw M G, Pratt C A, Gollan J K, Massion A O, . et al . Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up.  J Nerv Men Dis. 1994;  182 290-296
    PubMedGoogle Scholar
  • 31 Klein D F. Anxiety reconceptualized. In: Klein DF, Rabkin JG (eds) Anxiety: new research and changing concepts. New York; Raven Press 1980
    Google Scholar
  • 32 Lecrubier Y, Bakker A, Dunbar G, Judge R, . and the collaborative Paroxetine Panic Study Investigators . A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder.  Acta Psychiatr Scand. 1997;  95 145-152
    PubMedGoogle Scholar
  • 33 Lecrubier Y. The impact of comorbidity on the treatment of panic disorder.  J Clin Psychiatry. 1998;  59 ((Suppl. 8)) 11-14
    PubMedGoogle Scholar
  • 34 Lelliott P T, Marks I M, Montero W O, Tsakaris F, Noshirvani H. Agoraphobics 5 years after imipramine and exposure: outcome and predictors.  J Nerv Men Dis. 1987;  175 599-605
    PubMedGoogle Scholar
  • 35 Lesser I M, Rubin R T, Pecknold S C, Rufkin A, Swinson R P, Lydiard R B, . et al . Secondary depression in panic disorder and agoraphobia: frequency, severity and response to treatment.  Arch Gen Psychiatry. 1988;  45 437-443
    PubMedGoogle Scholar
  • 36 Liebowitz M R. Panic disorder as a chronic illness.  J Clin Psychiatry. 1997;  58 ((Suppl. 13)) 5-8
    PubMedGoogle Scholar
  • 37 Linden M. Phase IV Research and Drug Utilization Observation Studies.  Pharmacopsychiat. 1997;  30 ((1)) 1-3
    PubMedGoogle Scholar
  • 38 Linden M. Therapeutic standards in psychopharmacology and medical decision making.  Pharmacopsychiat. 1994;  27 41-45
    PubMedGoogle Scholar
  • 39 Maier W, Buller R. One-year follow-up of panic disorder.  Eur Arch Psychiatr Neurol Sci. 1988;  238 105-109
    PubMedGoogle Scholar
  • 40 Marks I. Phobic disorders four years after treatment: a prospective follow-up.  Br J Psychiatry. 1971;  118 683-688
    PubMedGoogle Scholar
  • 41 Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of Agoraphobia.  Am J Psychiatry. 1986;  143 1106-1112
    PubMedGoogle Scholar
  • 42 Mavissakalian M, Hamann M S. DSM-III personality disorder in agoraphobia. II. Changes with treatment.  Compr Psychiatry. 1987;  28 356-361
    CrossrefPubMedGoogle Scholar
  • 43 Mavissakalian M, Perel J. Clinical experiments in maintenance and discontinuation of imipramine therapy in Panic Disorder with Agoraphobia.  Arch Gen Psychiatry. 1992;  49 318-323
    PubMedGoogle Scholar
  • 44 Mavissakalian M, Perel J. Protective effect of imipramine maintenance treatment in panic disorder with agoraphobia.  Am J Psychiatry. 1992;  149 1053-1057
    PubMedGoogle Scholar
  • 45 Milrod B, Busch F. Long-term outcome of panic disorder: a review of the literature.  J Nerv Ment Dis. 1996;  184 723-730
    CrossrefPubMedGoogle Scholar
  • 46 Munby M, Johnston D W. Agoraphobia: the long-term follow-up of behavioural treatment.  Br J Psychiatry. 1980;  137 418-427
    PubMedGoogle Scholar
  • 47 Nagy L M, Krystal J H, Woods S W, Charney D S. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder.  Arch Gen Psychiatry. 1989;  46 993-999
    PubMedGoogle Scholar
  • 48 Nagy L M, Krystal J H, Charney D S. Long-term outcome of Panic Disorder after short-term imipramine and behavioral group treatment.  J Clin Psychopharmacology. 1993;  13 16-24
    PubMedGoogle Scholar
  • 49 Noyes R, Garvey M, Cook B. Follow-study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants.  J Affective Disorders. 1989;  16 249-257
    CrossrefPubMedGoogle Scholar
  • 50 Noyes R, Reich J, Christiansen J, Suelzer M, Pfohl B, Coryell W A. Outcome of Panic Disorder: relationship to dignostic subtypes and comorbidity.  Arch General Psychiatry. 1990;  47 809-818
    PubMedGoogle Scholar
  • 51 Noyes R, Garvey M J, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.  Am J Psychiatry. 1991;  148 517-523
    PubMedGoogle Scholar
  • 52 Noyes R, Clancy J, Woodsman C, Holt C S, Suelzer M, Christiansen J, . et al . Environmental factors related to the outcome of panic disorder: a seven-year follow-up study.  J Nerv Men Dis. 1993;  181 529-533
    PubMedGoogle Scholar
  • 53 O'Rourke D, Fahy T J, Brophy J, Prescott P. The Galway study of panic disorder III: outcome at 5 to 6 years.  Br J Psychiatry. 1996;  168 462-469
    PubMedGoogle Scholar
  • 54 O'Sullivan G, Marks I M. Long-term outcome of phobic and obessive-compulsive disorders after treatment. In: Noyes R, Burrows GD, Roth M (eds) Handbook of Anxiety. Vol. 4. Amsterdam; Elsevier 1990: 87-108
    Google Scholar
  • 55 Otto W. Integrated treatment of panic disorder.  J Clin Psychiatry. 1997;  58 36-42
    PubMedGoogle Scholar
  • 56 Pecknold J C. Discontinuation reactions to alprazolam in panic disorder.  J Psychiatr Res. 1993;  27 ((Suppl. 1)) 155-170
    PubMedGoogle Scholar
  • 57 Perugi G, Toni C, Benedetti A, Simonetti B, Simoncini M, Torti C, . et al . Delineating a putative phobic-anxious temperament in 126 panic-agoraphobic patients: toward a rapprochement of European and US views.  J Affect Dis. 1998;  47 ((1 - 3)) 11-23
    PubMedGoogle Scholar
  • 58 Placidi G F, Signoretta A, Liguori A, Gervasi R, Maremmani I, Akiskal H S. The semi-structured affective temperament interview (TEMPS-I). Reliability and psychometric properties in 1010 14-26 year old students.  J Affect Dis. 1998;  47 1-10
    CrossrefPubMedGoogle Scholar
  • 59 Pollack M H. Long-term management of panic disorder.  J Clin Psychiatry. 1990;  51 11-13
    PubMedGoogle Scholar
  • 60 Pollack M H, Otto M W, Rosenbaum J, Sachs G, O'Neil C, Asher R, . et al . Longitudinal course of Panic Disorder: finding from the Massachusetts General Hospital Naturalistic Study.  J Clin Psychiatry. 1990;  51 12-16
    PubMedGoogle Scholar
  • 61 Pollack M H, Otto M W. Long-term course and outcome of panic disorder.  J Clin Psychiatry. 1997;  58 ((Suppl. 2)) 57-60
    PubMedGoogle Scholar
  • 62 Reich J H. DSM-III personality disorders and the outcome of treated panic disorder.  Arch Gen Psychiatry. 1988;  145 1149-1152
    PubMedGoogle Scholar
  • 63 Roy-Byrne P P, Cowley D S. Course and outcome in panic disorder: a review of recent follow-up studies.  Anxiety. 1995;  1 151-160
    PubMedGoogle Scholar
  • 64 Scheibe G, Albus M. Predictors of outcome in panic disorder: a 5-year prospective follow-up study.  J Affect Disorder. 1996;  41 111-116
    PubMedGoogle Scholar
  • 65 Sheehan D V, Ballenger J, Jacobsen G. Treatment of endogenous anxiety.  Arch Gen Psychiatry. 1980;  37 51-59
    PubMedGoogle Scholar
  • 66 Sheehan D. The anxiety disease. New York; Bantam Books 1986
  • 67 Solyom L, Heseltine G FD, McClure D J, . et al . Interaction of phenelzine and exposure in phobias.  Can Psychiatr Assn J. 1973;  18 25-32
    PubMedGoogle Scholar
  • 68 Spitzer R L, Williams J BW. Structured clinical interview for DSM-III (SCID). In: Reidel D, Dordrecht (ed) New York, NY; Biometrics Research Department, State Psychiatric Institute 1983
  • 69 Spitzer R L, Williams J BW, Gibbon M, First M B. Structured Clinical Interview for DSM-III Personality Disorders (SCID-II). Washington, DC; American Psychiatric Press 1990
  • 70 Toni C, Cassano G B, Perugi G, Murri L, Mancino M, Petracca A, . et al . Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy.  Comprehensive Psychiatry. 1996;  37 ((2)) 125-133
    CrossrefPubMedGoogle Scholar
  • 71 Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety.  Psychopharmacology. 1973;  32 237-254
    PubMedGoogle Scholar
  • 72 Tyrer T. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment.  J Affective Disord. 1984;  6 1-7
    CrossrefPubMedGoogle Scholar
  • 73 Van Balkom A J, Bakker A, Spinhoven P, Blaauw B M, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments.  J Nerv Ment Dis. 1997;  185 ((8)) 510-516
    CrossrefPubMedGoogle Scholar
  • 74 Van Valkenburg C, Akiskal H S, Puzantian V, . et al . Anxious depressions: clinical, family history, and naturalistic outcome: comparisons with panic and major depressive disorders.  J Affect Disord. 1984;  6 67-82
    CrossrefPubMedGoogle Scholar
  • 75 Warshaw M G, Massion A O, Shea M T, Allsworth J, Keller M B. Predictors of remission in patients with panic with and without agoraphobia: prospective 5-year follow-up data.  J Nerv Ment Dis. 1997;  185 ((8)) 517-519
    CrossrefPubMedGoogle Scholar
  • 76 Wittchen H-U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich follow-up study. In: Hand I, Wittchen H-U (eds) Panic and phobias 2. Berlin; Sperlag 1988: 3-17
    Google Scholar
  • 77 Zitrin C M, Klein D F, Woemer M G. Treatment of agoraphobia with group exposure in vivo and imipramine.  Arch Gen Psychiatry. 1980;  37 63-72
    PubMedGoogle Scholar

Dr. Giulio Perugi

Institute of Psychiatry

via Roma 67

56100 Pisa

Italy

Phone: +39-050-992543

Email: gperugi@psico.med.unipi.it

      >